Data analysis of PD-1 antibody in the treatment of melanoma patients.

Data presented in this article are supplementary materials to the research article entitled “IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma”. Data for melanoma patients who did not receive anti-PD-1 treatment were obtained from Tianjin Medical University Cancer Institute & Hospital from February 1981 to May 2013. Kaplan–Meier was used for survival analysis. RNA sequencing data from 28 melanoma patients receiving anti-PD-1 therapy were download from GEO database (GSE78220). Cluster analysis of RNA expression was performed using R (package pheatmap). The difference of PD-L1 expression was analysed by the Boxplot (R ggplot2 package). Differences between each group were analyzed by Fisher exact test. Information of 13 melanoma patients who had failed prior chemotherapy and treated in the Tianjin Medical University Cancer Institute & Hospital between July 2015 and December 2018 was collected. The response was captured by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1).


a b s t r a c t
Data presented in this article are supplementary materials to the research article entitled "IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma". Data for melanoma patients who did not receive anti-PD-1 treatment were obtained from Tianjin Medical University Cancer Institute & Hospital from February 1981 to May 2013. Kaplan-Meier was used for survival analysis. RNA sequencing data from 28 melanoma patients receiving anti-PD-1 therapy were download from GEO database (GSE78220). Cluster analysis of RNA expression was performed using R (package pheatmap). The difference of PD-L1 expression was analysed by the Boxplot (R ggplot2 package). Differences between each group were analyzed by Fisher exact test. Information

Value of the data
• The present data show the characteristics of melanoma patients with or without anti-PD-1 treatment from RNA and protein levels. The data might contain valuable information on the clinical use of anti-PD-1 agents. • These data are preliminary exploration of combined IGFBP2 and PD-L1 as reliable biomarkers to predict the efficacy of anti-PD-1/PD-L1 therapy. These data and methods provide direction for further expanding research and other reliable biomarkers.

Data description
These data show the expression characteristics of malignant melanoma patients with or without anti-PD-1 treatment at RNA and protein levels. As for melanoma patients who did not receive anti-PD-1 treatment, data were collected from Tianjin Medical University Cancer Institute & Hospital from February 1981 to May 2013. The multivariate analysis data are shown in Table 1 . The RNA sequencing data from 28 melanoma patients receiving anti-PD-1 therapy were obtained  Table 2 The ROC analysis the response for IGFBP2, PD-L1 and TWO -HIGH groups to anti-PD-1 treatment.  from the GEO database (GSE78220) ( Supplementary Information 1). According to the response to anti-PD-1 treatment, patients were divided into two groups: response and non-response group. Bioinformatic analysis are shown in Fig. 1 . The ROC analysis of the data in Table 2 Table 3 . The efficacy evaluation and protein expression characteristics of anti-PD-1 treatment were shown in Figs. 2 and 3 . Furthermore, Fig. 2 and Table 3 are related, and Fig. 3 is representing an IHC summary on subset of patients that have been listed in Table 2 .

Bioinformatic analysis of RNA sequencing data of melanoma patients with anti-PD-1 therapy (GSE78220)
Analysis of RNA sequencing data from the GEO database (GSE78220), which includes 28 patients with malignant melanoma who received anti-PD-1 treatment [1] . According to the Table 3 Clinical characteristics of 13 Chinese melanoma patients in stage IV who received anti-PD-1 treatment.  response to anti-PD-L1 treatment, patients were divided into two groups: response and nonresponse groups. Cluster analysis of RNA expression was performed using R (package pheatmap). The difference in the mRNA expression of PD-L1 was analyzed by the Boxplot (R ggplot2 package). According to the median mRNA levels of IGFBP2 and PD-L1, the 28 patients were divided into four groups (high IGFBP2 + high PD-L1, high IGFBP2 + low PD-L1, low IGFBP2 + high PD-L1 and low IGFBP2 + low PD-L1). Differences among the four groups were analyzed by Fisher exact test. * p < 0.05, * * p < 0.01, and * * * p < 0.001.

Anti-PD-1 treatment efficacy and assessment
Data were collected from 13 melanoma patients who had failed prior chemotherapy and treated in the Tianjin Medical University Cancer Institute & Hospital between July 2015 and December 2018. These patients had unresectable stage III or IV malignant melanoma. The therapeutic dose of Keytruda (pembrolizumab) was 2 mg/kg, once every three weeks, and the therapeutic dose of Opdivo (nivolumab) was 3 mg/kg, once every two weeks. The cancer immunotherapy response was captured by Response Evaluation Criteria in Solid Tumors (RECIST) [2 , 3] . Tumors were reduced by at least 30% for more than 4 weeks is considered a partial response (PR). The maximum diameter of the target lesion increased by at least 20% or new lesions were identified as disease progression (PD). The sum of the maximum diameter of the target lesion reduced to less than PR or increased to less than PD was considered stable disease (SD).